Dexycu (dexamethasone intraocular injection)
/ EyePoint Pharma, Ocumension Therap
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
90
Go to page
1
2
3
4
July 12, 2024
A Real-world Study of DEXYCU in the Treatment of Inflammation After Cataract Surgery
(clinicaltrials.gov)
- P4 | N=263 | Completed | Sponsor: Ocumension Therapeutics (Shanghai) Co., Ltd
New P4 trial • Real-world • Real-world evidence • Surgery • Cataract • Inflammation • Ocular Inflammation • Ophthalmology
May 24, 2024
Study of Dexycu in Treating Intraocular Inflammation
(clinicaltrials.gov)
- P3 | N=285 | Completed | Sponsor: Ocumension Therapeutics (Shanghai) Co., Ltd
New P3 trial • Cataract • Inflammation • Ocular Inflammation • Ophthalmology
April 05, 2024
A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery (2)
(clinicaltrials.gov)
- P3 | N=0 | Withdrawn | Sponsor: EyePoint Pharmaceuticals, Inc. | Trial completion date: Apr 2024 ➔ Sep 2023 | Trial primary completion date: Apr 2024 ➔ Sep 2023
Surgery • Trial completion date • Trial primary completion date • Cataract • Ophthalmology • Pain
February 22, 2024
Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract
(clinicaltrials.gov)
- P4 | N=60 | Recruiting | Sponsor: EyePoint Pharmaceuticals, Inc. | Trial completion date: Feb 2024 ➔ Feb 2025 | Trial primary completion date: Jan 2024 ➔ Jan 2025
Surgery • Trial completion date • Trial primary completion date • Cataract • Inflammation • Ocular Inflammation • Ophthalmology
September 08, 2023
A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery (2)
(clinicaltrials.gov)
- P3 | N=0 | Withdrawn | Sponsor: EyePoint Pharmaceuticals, Inc. | N=150 ➔ 0 | Not yet recruiting ➔ Withdrawn
Enrollment change • Surgery • Trial withdrawal • Cataract • Ophthalmology • Pain
June 15, 2023
Omidria and Dexycu, or Omidria and Dextenza Compared to Topical Prednisolone Acetate 1% Following Cataract Surgery
(clinicaltrials.gov)
- P4 | N=15 | Completed | Sponsor: Silverstein Eye Centers | Unknown status ➔ Completed | N=75 ➔ 15
Enrollment change • Surgery • Trial completion • Cataract • Inflammation • Ophthalmology • Pain
March 30, 2023
SELVEDge: Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
(clinicaltrials.gov)
- P2 | N=33 | Recruiting | Sponsor: University of Miami | Not yet recruiting ➔ Recruiting
Enrollment open • Hematological Malignancies • Multiple Myeloma • Oncology
March 24, 2023
Utilization and Cost of Novel Sustained-Release Steroids for Cataract Surgery Among Medicare Beneficiaries
(ASCRS-ASOA 2023)
- "Purpose To examine the utilization and costs of novel sustained-release steroids, dexamethasone intraocular suspension (DEXYCU) and dexamethasone ophthalmic insert (DEXTENZA), in Medicare patients undergoing cataract surgery in the US.MethodsThis was a retrospective, cross-sectional analysis on all Medicare Fee-For-Service beneficiaries aged 65 years or older who underwent at least one cataract surgery from March 2019 to December 2021.Claims for cataract surgery and concurrent utilization of dexamethasone intraocular suspension or dexamethasone ophthalmic insert were identified by billing codes.Information on patient and surgeon demographic characteristics and cost of surgery and drugs were extracted to determine the utilization rate and cost.A hierarchical multivariable logistic regression model was used to evaluate different factors associated with increased utilization of novel sustained-release steroids.ResultsOut of a total of 4,252,532 cataract surgeries performed,..."
Medicare • Reimbursement • Surgery • US reimbursement • Cataract • Ophthalmology
September 07, 2022
SELVEDge: Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
(clinicaltrials.gov)
- P2 | N=33 | Not yet recruiting | Sponsor: University of Miami
New P2 trial • Hematological Malignancies • Multiple Myeloma • Oncology
September 22, 2022
A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery (2)
(clinicaltrials.gov)
- P3 | N=150 | Not yet recruiting | Sponsor: EyePoint Pharmaceuticals, Inc.
New P3 trial • Cataract • Ophthalmology • Pain
September 22, 2022
A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery
(clinicaltrials.gov)
- P3 | N=150 | Not yet recruiting | Sponsor: EyePoint Pharmaceuticals, Inc.
New P3 trial • Cataract • Ophthalmology • Pain
June 28, 2022
Real-World Experience with Intracapsular Administration of Dexamethasone Intraocular Suspension 9% for Control of Postoperative Inflammation.
(PubMed, Clin Ophthalmol)
- "DEXYCU (dexamethasone intraocular suspension) 9% is the first and only intraocular corticosteroid FDA-approved for postoperative inflammation, whose sustained-release formulation provides a high initial release of drug, followed by a gradual tapering...This technique also minimizes contact with metabolically active tissues such as the corneal endothelium, iris, and ciliary body. In this paper, we review the available literature on dexamethasone intraocular suspension and summarize surgeons' consensus on best practices for intracapsular administration."
Journal • Real-world evidence • Review • Cataract • Immunology • Inflammation • Ocular Inflammation • Ophthalmology
April 26, 2022
Anterior Chamber Versus Intravitreal Administration of Dexamethasone 9% Suspension in Cataract Patients with and without Glaucoma
(ASCRS-ASOA 2022)
- "MethodsRetrospective data were collected from patients who received dexamethasone 9% suspension (DEXYCU®; EyePoint Pharmaceuticals) either via anterior chamber administration (on-label) or intravitreal injection (off-label) after cataract surgery, with/without minimally invasive glaucoma surgery (MIGS)...All patients were given intracameral moxifloxacin at the time of surgery...1 patient in the IVD required rescue medications compared to 8 patients in the ACD group (p<0.01). Conclusion Administration of IVD or ACD does not impede the intraocular pressure reduction produced by cataract surgery combined with MIGS."
Clinical • Cataract • Glaucoma • Ophthalmology
March 16, 2022
". @LisaNijmMDJD shares her pearls for successful capsular bag administration of dexamethasone #intraocular suspension 9% https://t.co/y4DiF8qBLD #Ophthalmology #Dexycu @EyePointPharma #Surgery"
(@OphthTimes)
Ophthalmology
January 13, 2022
A Study to Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract
(clinicaltrials.gov)
- P4; N=60; Recruiting; Sponsor: EyePoint Pharmaceuticals, Inc.
Clinical • New P4 trial • Cataract • Immunology • Inflammation • Ocular Inflammation • Ophthalmology
December 21, 2021
Iris Atrophy After Administration of Intracameral Dexycu in Routine Cataract Surgery: A Case Series.
(PubMed, Eye Contact Lens)
- "None of the five eyes treated with traditional anti-inflammatory drops developed iris atrophy. The Dexycu intraocular dexamethasone implant was designed to mitigate postoperative inflammation and reduce need for topical therapy but may be associated with other potential adverse effects that warrant consideration."
Clinical • Journal • Cataract • Immunology • Inflammation • Ophthalmology
November 21, 2021
". @LisaNijmMDJD shares her pearls for successful capsular bag administration of dexamethasone intraocular suspension 9% https://t.co/s7nEHVogrK #Ophthalmology #Dexycu @EyePointPharma #Surgery"
(@OphthTimes)
Ophthalmology
November 11, 2021
". @LisaNijmMDJD shares her pearls for successful capsular bag administration of dexamethasone intraocular suspension 9% https://t.co/kEgQR9KQOU #Ophthalmology #Dexycu @EyePointPharma #Surgery"
(@OphthTimes)
Ophthalmology
October 20, 2021
Utilization and Cost-Analysis of Novel Dropless Steroid Alternatives for Cataract Surgery Among Medicare Beneficiaries
(AAO 2021)
- "Utilization and cost of dexamethasone intraocular suspension (Dexycu) and ophthalmic insert (Dextenza) were evaluated using HCPCS codes J1095 and J1096, respectively. Conclusion Dropless dexamethasone delivery technologies address patient inconvenience and poor compliance but entail disproportionately high costs compared to traditional steroid drops. This may explain the low adoption rates of these new drug delivery technologies, despite their pass-through status."
HEOR • Medicare • Reimbursement • Cataract • Ophthalmology
October 20, 2021
V06 - The Capsular Bag: A New Site for Drug Delivery
(AAO 2021)
- "This study evaluating the injection of Dexycu into a new location, the capsular bag, proved very promising. It was conducted independently and without support of the manufacturer."
Cataract • Ophthalmology
November 06, 2020
Injecting New Life Into Cataract Surgery
- "'Minimizing the eye drop burden for patients is an important goal,' says Cynthia Matossian, MD...'Regimens can be confusing, especially for the older patient population who undergo cataract surgery, and can be bothersome to patients who resent having to follow a drop schedule that might interfere with their daily activities. Compliance with prescribed post-op regimens is a significant issue, and limiting the number of drops they have to self-administer has the potential to improve outcomes.'"
Media quote
July 20, 2021
"$EYPT EyePoint Pharmaceuticals Receives Preliminary Extension to Pass-Through Payment Status for DEXYCU® https://t.co/Z3NLl3KODA"
(@stock_titan)
July 19, 2021
My Preferred Approach to Post-Operative Cataract Drug-Delivery: Dexycu/Dextenxa
(ASCRS-ASOA 2021)
- No abstract available
Cataract • Ophthalmology
July 19, 2021
The D3 Study: Drug Delivery Vs Drops--Dexycu Vs Prednisolone Acetate for Pain & Inflammation in Sequential Cataract Surgery
(ASCRS-ASOA 2021)
- "Purpose To evaluate the patient experience of each eye in cataract surgery when one eye is treated with a minimum drops regimen, including an intraocular depot of dexamethasone (Dexycu, EyePoint) and intracameral moxifloxacin, and the other eye is treated with topical drops (prednisolone acetate and moxifloxacin drops). MethodsPatient preference, pain, macular thickness, and cost of medications will be measured, as well as patient-reported out-of-pocket cost of each regimen. ResultsTBDConclusionTBD"
Cataract • Immunology • Inflammation • Ophthalmology • Pain
July 19, 2021
Capsular Bag: A New Site for Drug Delivery
(ASCRS-ASOA 2021)
- "While VR surgeons have enjoyed innovation in drug delivery, cataract surgeons have had to accept topical therapy for decades despite disadvantages. This independent study evaluated the injection of Dexycu into a new location, the capsular bag."
Cataract • Ophthalmology
1 to 25
Of
90
Go to page
1
2
3
4